WELCOME to bigdna ltd
BigDNA Ltd is developing small molecule cancer therapies using a novel delivery and drug activation technology. This proprietary technology aims to increase the therapeutic window of the delivered drug whilst simultaneously reducing non-specific toxicity. BigDNA also retains the rights to its patented phage DNA vaccine technology.
BigDNA is a well capitalised company and currently has a diverse, well structured investor portfolio to allow us to develop our platform vaccine technology through phase I trials.
BigDNA has both a strong, focussed product development program built on key products and an active research arm, whose aim is to develop the core platform technology and to expand the range of vaccines delivered.
BigDNA actively seeks to work with academic and industrial partners who may be interested in research and development using our novel platform.